Zentalis Announces Intermittent Azenosertib Monotherapy Dosing Nearly Doubles…
ORR of 36.8% in heavily pretreated platinum-resistant ovarian cancer and USC patients treated with intermittent dosing Establishes monotherapy RP2D of 400 mg QD with 5:2 dosing…